EMVision Medical Devices Limited (ASX:EMV) has obtained further positive interim analysis from the latest phase of its clinical trials focused on advancing EMVision’s neurodiagnostic AI algorithms to aid in the diagnosis of suspected haemorrhagic or ischaemic stroke.
In Stage 2 of the pre-validation trial, a total of 180 patients were enrolled. Patients presented to the emergency department with stroke-like symptoms, across the three trial sites: Liverpool Hospital, Royal Melbourne and Princess Alexandra Hospital Brisbane.
Data from Stage 2 is being used to enhance AI algorithms, per protocol. Cross validation interim analysis has been undertaken to prepare for the upcoming Validation (sensitivity/specificity confirmation) trial.
The neurodiagnostic capabilities shown in this interim cross validation analysis across Stage 2 data continue to demonstrate the potential of the EMVision technology to significantly improve the diagnosis, care, and outcomes for both haemorrhagic and ischaemic stroke patients, from early at the patient presentation, including prioritised care of hyperacute/acute strokes (as opposed to stroke mimics), at the point-of-care.
“The positive interim results for ischaemia detection, considered alongside those previously for haemorrhage detection, illustrate the technology’s evolving capability in addressing 2 of the most pressing questions at acute suspected stroke presentation: is there a stroke, and if so is it haemorrhagic or ischaemic? “Principal investigator at Royal Melbourne Hospital Dr Angela Dos Santos said.
“Timely answering of these questions allow the most effective care pathway to be activated as early as possible.”
